ARTICLE | Product Development
All in the family
Next-generation EGFR inhibitors at ASCO: bigger blockade, more efficacy in cancer
June 14, 2010 7:00 AM UTC
The idea behind the next generation of EGFR inhibitors is to provide greater blockade of the receptors than marketed agents. Roche, Pfizer Inc. and Boehringer Ingelheim GmbH presented data at the American Society of Clinical Oncology meeting showing potential for their next-generation products to have better efficacy than the first generation.
The first-generation drugs each target a single EGFR. For example, Herceptin trastuzumab from Roche's Genentech Inc. unit is a humanized mAb against EGFR 2 (HER2; ErbB2; neu). It is approved for HER2-positive breast cancer...